Trials / Recruiting
RecruitingNCT07465224
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALN-4324 | ALN-4324 will be administered subcutaneously (SC). |
| DRUG | Placebo | Placebo will be administered SC. |
Timeline
- Start date
- 2026-01-15
- Primary completion
- 2027-05-28
- Completion
- 2027-05-28
- First posted
- 2026-03-11
- Last updated
- 2026-04-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07465224. Inclusion in this directory is not an endorsement.